Romiplostim + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Immune Thrombocytopenia
Conditions
Immune Thrombocytopenia
Trial Timeline
Sep 1, 2015 → Jun 1, 2017
NCT ID
NCT02868099About Romiplostim + Placebo
Romiplostim + Placebo is a phase 3 stage product being developed by Kyowa Kirin for Immune Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02868099. Target conditions include Immune Thrombocytopenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02868099 | Phase 3 | Completed |
Competing Products
20 competing products in Immune Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pirtobrutinib + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 44 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Placebo + Lusutrombopag | Shionogi | Phase 2 | 52 |
| Lusutrombopag | Shionogi | Phase 2 | 52 |
| Romiplostim | Kyowa Kirin | Phase 1/2 | 41 |
| AMG 531 | Kyowa Kirin | Phase 2/3 | 65 |
| Romiplostim (AMG-531) | Kyowa Kirin | Phase 2 | 52 |
| Romiplostim and danazol | Kyowa Kirin | Phase 2 | 52 |
| Hetrombopag Olamine | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR0302 quick release tablets + SHR0302 sustained-release tablets | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| HR19042 Capsule, Tarpeyo®, Budenofalk® | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HR19042 Capsules | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Herombopag | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Zostavax® | Merck | Pre-clinical | 23 |
| Raltegravir + Atazanavir | Merck | Pre-clinical | 23 |
| Zostavax | Merck | Pre-clinical | 23 |
| MK-8723 + Matching Placebo | Merck | Phase 1 | 33 |
| Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM | Novartis | Phase 2 | 52 |